--- title: "Beyond Big Tech: 10 Under-the-Radar US Stocks Making Moves This Week" type: "News" locale: "en" url: "https://longbridge.com/en/news/292261154.md" description: "While major indices focus on tech giants, niche US markets are seeing massive strategic shifts. From high-stakes biopharma litigation to rapid commercialization in enterprise AI, these under-the-radar names are experiencing pivotal catalysts." datetime: "2026-07-10T02:02:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292261154.md) - [en](https://longbridge.com/en/news/292261154.md) - [zh-HK](https://longbridge.com/zh-HK/news/292261154.md) --- # Beyond Big Tech: 10 Under-the-Radar US Stocks Making Moves This Week While the broader market remains fixated on Big Tech's every move, there's a lot of quiet restructuring and strategic maneuvering happening in the niche corners of the US equities market. I'm told that several under-the-radar names across healthcare, enterprise AI, and regional banking are bracing for significant shifts. Here is a look at what else is going on this week. ### Bristol-Myers Squibb CVR (CELG.RT.US) The saga surrounding the contingent value rights (CVR) tied to Bristol Myers Squibb's acquisition of Celgene continues to unfold. According to people familiar with the matter, former Celgene shareholders recently filed a massive USD 6.4 billion lawsuit, alleging that BMS deliberately stalled the FDA approval process for its cancer drug to avoid the payout. Although Bristol-Myers Squibb CVR (CELG.RT.US) is no longer traded on the NYSE, this legal battle over "diligent efforts" remains a high-stakes cautionary tale for biopharma M&A. ### Rezolve AI (RZLV.US) Rezolve AI (RZLV.US) is making an aggressive push in the conversational commerce space. The company reported that its unaudited Q1 2026 revenue hit USD 60 million—already surpassing its entire full-year 2025 top line. In early July, Rezolve launched "Auditable AI" to provide human-readable explanations for AI recommendations, aiming to solve the enterprise trust gap. On top of that, shareholders overwhelmingly approved a share buyback mandate of up to USD 300 million, which could take effect by mid-September. ### Oil-Dri Corp of America (ODC.US) Oil-Dri Corp of America (ODC.US) has shown resilient year-to-date performance. Management is targeting broad price increases in the first quarter of fiscal 2027 to offset rising external costs, including freight and resin-based packaging. This bold pricing strategy comes on the heels of a record-breaking third quarter for sales and the company's 23rd consecutive annual dividend hike. ### CVB Financial (CVBF.US) The regional banking sector is seeing consolidation, and CVB Financial (CVBF.US) is capitalizing on it. Following the completion of its merger with Heritage Commerce Corp in April 2026—which pushed its total assets past the USD 20 billion mark—the board authorized a new repurchase program for up to 15 million shares. I'm told this aggressive buyback replaces the previous 2024 plan entirely, reflecting management's confidence after a solid Q1 2026 where net interest income rose 6.7% year-over-year. ### Brand Engagement Network (BNAI.US) Recently added to both the Russell 3000 and 2000 indices, Brand Engagement Network (BNAI.US) has had its strongest quarter since going public. The enterprise AI firm completed its USD 19.5 million acquisition of Cataneo—a profitable software provider with over EUR 8.6 million in 2025 revenue—in late June. BNAI also pushed its Skye Salud platform into Phase 2 trials in Mexico, signaling a rapid global expansion. ### NeuroPace (NPCE.US) NeuroPace (NPCE.US) continues to outperform many of its medtech peers this year. The company secured FDA clearance for ECoG Assistant™ in late May 2026, marking its first AI-driven feature utilizing its massive long-term intracranial EEG dataset. Buoyed by this regulatory win and a strong Q1 2026 earnings report, management has raised its full-year revenue guidance. ### Also in the news... - **Foghorn Therapeutics (FHTX.US)**: The clinical-stage biotech firm recently provided a Q1 2026 update and continues to pitch its precision medicine pipeline to investors, making a notable appearance at the Goldman Sachs global healthcare conference in June. - **CEMIG (CIG.US)**: The Brazilian power utility posted Q1 2026 net operating revenue of BRL 10.46 billion. However, higher financial expenses and energy purchase costs slightly pressured its bottom line, keeping investors watchful on its distribution efficiency. - **iShares Gold Trust (IAUM.US)**: Tracking the price of gold bullion, the trust has seen a mid-single-digit pullback year-to-date, though it remains a massive vehicle for physical gold exposure with over USD 60 billion in AUM. - **CareView Communications (CRVW.US)**: The OTC-traded healthcare IT provider continues to carve out its niche, steadily deploying its video monitoring and patient safety systems across US hospitals. _This article does not constitute investment advice._ ### Related Stocks - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) - [RZLV.US](https://longbridge.com/en/quote/RZLV.US.md) - [ODC.US](https://longbridge.com/en/quote/ODC.US.md) - [CVBF.US](https://longbridge.com/en/quote/CVBF.US.md) - [BNAI.US](https://longbridge.com/en/quote/BNAI.US.md) - [NPCE.US](https://longbridge.com/en/quote/NPCE.US.md) - [FHTX.US](https://longbridge.com/en/quote/FHTX.US.md) - [CIG.US](https://longbridge.com/en/quote/CIG.US.md) ## Related News & Research - [CVB Financial director Raymond V. O’Brien III acquires 20,000 common shares valued at $455,300](https://longbridge.com/en/news/294114745.md) - [NeuroPace says FDA deems epilepsy label expansion filing not approvable in current form](https://longbridge.com/en/news/294110473.md) - [Cemig audit committee reviews customer database cyber incident at June 10 meeting](https://longbridge.com/en/news/294102918.md) - [Oil-Dri’s Amlan to exhibit at SIAVS 2026 with poultry feed additive lineup](https://longbridge.com/en/news/294106020.md) - [Cvb Financial Leans On Heritage Deal For Growth](https://longbridge.com/en/news/293686110.md)